Generics in the Antivirals Market to 2018 - Launch of Generic Combivir and Patent Expiry of Sustiva, Kaletra and Epivir-HBV will Drive Volume Growth

Summary

GBI Research in its present report Generics in the Antivirals Market to 2018 - Launch of Generic Combivir and Patent Expiry of Sustiva, Kaletra and Epivir-HBV will Drive Volume Growth describes generic market in antiviral therapeutics. This report covers antiviral therapeutics including HIV therapeutics, Hepatitis therapeutics, Herpes therapeutics, CMV therapeutics and Influenza therapeutics. Generics in antiviral market are forecast to grow at a CAGR of 10.5% during 2010-2018, largely due to series of patent expiries in the antiviral market. In 2010 generic HIV/AIDS therapeutic market sales contributes 46% market share in the total generic antiviral therapeutic market followed by generic herpes therapeutic market with 39.6% of market share. It is estimated that in 2010, generics accounted for 18.9% of market share in global antivirals market, and this market share is forecast to grow and reach 29.2% by 2018.

Generics in global antivirals market are estimated to be $4.2 billion in 2010 and are forecast to grow at a CAGR of 10.5% and reach $9.2 billion by 2018. From 2004, the market grew at a CAGR of 21.1% to reach $4.2 billion in 2010. Global generic antiviral market is comprised of revenues generated by various generic antiviral drugs. In 2010, it is estimated that generics in HIV market accounted for largest market share in total generic antivirals market. Generics in HIV market accounted for 46% of market share in total generic antivirals market in 2010, while generic herpes therapeutics accounted for 39.6% of market share. Generic influenza therapeutics accounted for 1% of total market share. Generic CMV market holds about 9.6% of share in total antiviral generic market, while generic hepatitis market accounted for only 3.9% of market share.

Series of patent expiries of key antiviral drugs will positively impact the market. Increase in patient population, reforms in government policies towards the use of generic drugs could be other major drivers of the market during the forecast period.

GBI Research projects that global generic HIV market will grow at a CAGR of 6.7% during 2010-2018. Growth in the market could be attributed to loss of patent exclusivity of key antiviral drugs. The market is currently dominated by products such as zidovudine, didanosine, stavudine and lamivudine. Launch of Combivir (lamivudine/Zidovudine) is expected soon, which can significantly influence the market.

GBI Research forecasts that global generic herpes market will grow at a CAGR of 9% during 2010-2018. Global generic herpes therapeutics market grew at a rapid rate of 32.4% from 2004 to 2010. The market revenue during this period was driven primarily by generic product such as acyclovir. In 2009, after patent expiry of Valtrex (valacyclovir), its generic equivalents were launched. In 2010, Famvir (famciclovir), potent antiviral from Novartis lost its patent exclusivity and its generic equivalents are currently available. In April, 2011, Mylan launched generic version of famciclovir.

Scope

- Data and analysis on the global generics in antivirals market
- Market forecasts for the global generics in antivirals market until 2018
- Market Data on geographical landscape including country wise coverage, cost of therapy, market size and market share.
- Key drivers and restraints that have created significant impact on the market.
- Competitive landscape of the global generics in antivirals market including top companies profiles. The key companies studied in this report are Teva Pharmaceuticals, Aurobindo Pharma, Mylan Inc and Watson Pharmaceuticals.
- Key M&A activities, Licensing Agreements, that have taken place between 2007 and 2011 in the global generics in antivirals market.

Reasons to buy

The r